Insider Selling: Renovaro Inc. (NASDAQ:RENB) Major Shareholder Sells 50,000 Shares of Stock

Renovaro Inc. (NASDAQ:RENB) major shareholder Anderson Wittekind William sold 50,000 shares of the firm’s stock in a transaction dated Wednesday, July 3rd. The shares were sold at an average price of $1.51, for a total value of $75,500.00. Following the completion of the transaction, the insider now owns 1,034,275 shares in the company, valued at approximately $1,561,755.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Anderson Wittekind William also recently made the following trade(s):

• On Friday, July 5th, Anderson Wittekind William sold 60,000 shares of Renovaro stock. The shares were sold at an average price of $1.55, for a total transaction of $93,000.00.
• On Monday, July 1st, Anderson Wittekind William sold 60,000 shares of Renovaro stock. The shares were sold at an average price of $1.56, for a total transaction of $93,600.00.
• On Thursday, June 27th, Anderson Wittekind William sold 14,671 shares of Renovaro stock. The stock was sold at an average price of $1.50, for a total transaction of $22,006.50.
• On Tuesday, June 25th, Anderson Wittekind William sold 20,000 shares of Renovaro stock. The shares were sold at an average price of $1.58, for a total value of $31,600.00.
• On Friday, June 14th, Anderson Wittekind William sold 50,000 shares of Renovaro stock. The stock was sold at an average price of $1.58, for a total value of $79,000.00.

Renovaro Trading Up 0.7 %

Shares of RENB opened at $1.52 on Thursday. The stock has a market cap of $224.22 million, a P/E ratio of -1.95 and a beta of 0.60. The stock’s 50-day moving average price is $1.40 and its two-hundred day moving average price is $2.50. Renovaro Inc. has a 1 year low of $0.48 and a 1 year high of $5.25.

Renovaro (NASDAQ:RENB) last issued its quarterly earnings data on Wednesday, May 15th. The company reported ($0.08) earnings per share (EPS) for the quarter.

Hedge Funds Weigh In On Renovaro

Several institutional investors and hedge funds have recently made changes to their positions in RENB. SG Americas Securities LLC bought a new position in Renovaro during the first quarter worth about $46,000. Tidal Investments LLC acquired a new stake in shares of Renovaro during the first quarter worth about $98,000. Finally, Vanguard Group Inc. lifted its holdings in shares of Renovaro by 904.0% during the 1st quarter. Vanguard Group Inc. now owns 3,916,672 shares of the company’s stock valued at $10,379,000 after purchasing an additional 3,526,565 shares in the last quarter. Institutional investors and hedge funds own 71.41% of the company’s stock.

About Renovaro

Renovaro Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV.